Your browser doesn't support javascript.
loading
Chemogenetic ON and OFF switches for RNA virus replication.
Heilmann, E; Kimpel, J; Hofer, B; Rössler, A; Blaas, I; Egerer, L; Nolden, T; Urbiola, C; Kräusslich, H G; Wollmann, G; von Laer, D.
  • Heilmann E; Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria.
  • Kimpel J; Christian Doppler Laboratory for Viral Immunotherapy of Cancer, Medical University of Innsbruck, Innsbruck, Austria.
  • Hofer B; Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria.
  • Rössler A; Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria.
  • Blaas I; Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria.
  • Egerer L; Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria.
  • Nolden T; Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria.
  • Urbiola C; ViraTherapeutics GmbH, Innsbruck, Austria.
  • Kräusslich HG; Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria.
  • Wollmann G; ViraTherapeutics GmbH, Innsbruck, Austria.
  • von Laer D; Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria.
Nat Commun ; 12(1): 1362, 2021 03 01.
Article en En | MEDLINE | ID: mdl-33649317
ABSTRACT
Therapeutic application of RNA viruses as oncolytic agents or gene vectors requires a tight control of virus activity if toxicity is a concern. Here we present a regulator switch for RNA viruses using a conditional protease approach, in which the function of at least one viral protein essential for transcription and replication is linked to autocatalytical, exogenous human immunodeficiency virus (HIV) protease activity. Virus activity can be en- or disabled by various HIV protease inhibitors. Incorporating the HIV protease dimer in the genome of vesicular stomatitis virus (VSV) into the open reading frame of either the P- or L-protein resulted in an ON switch. Here, virus activity depends on co-application of protease inhibitor in a dose-dependent manner. Conversely, an N-terminal VSV polymerase tag with the HIV protease dimer constitutes an OFF switch, as application of protease inhibitor stops virus activity. This technology may also be applicable to other potentially therapeutic RNA viruses.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Virus ARN / Replicación Viral Límite: Animals / Humans Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Virus ARN / Replicación Viral Límite: Animals / Humans Idioma: En Año: 2021 Tipo del documento: Article